Welcome to Beacon Equity Research. Today is Thursday, 13 September 2007  
 Home     Covered Companies     News and Commentary     Our Team     Ratings     Resources     Contact Us    
 
Untitled Document
 
Untitled Document Affiliates
Untitled Document
Untitled Document
Untitled Document
Untitled Document
Untitled Document
Untitled Document
Untitled Document
Untitled Document


ORAMED PHARMACEUTICL (OTC BB:ORMP.OB)

Understanding diabetes and the role of insulin
Diabetes is a common condition in which the amount of glucose (sugar) in the blood is too high because the body is unable to use it properly. This is because the body´s method of converting glucose into energy is not working as it should. Diabetes can lead to serious complications, such as heart disease, strokes, amputations, eye and kidney damage, and premature death. In developing countries, diabetes is the fourth-ranking cause of death.

Without question, diabetics have been slaves to syringes long enough. An effective insulin capsule has been long awaited by diabetics everywhere. Fortunately, Oramed is working to turn their dream into a reality in the near future.

Oramed´s accomplished team is preparing to move its patented technology towards clinical trials, to be conducted at the Hadassah University Hospital in Jerusalem. All products to be used in the trials will adhere to strict GMP standards, and a well-known pharmaceutical company will be employed to produce the oral insulin.

History will change when Oramed makes painless insulin delivery a reality for diabetes sufferers all over the world.

 
< Prev   Next >

 
Copyright 2007 Beacon Equity Research